The leadership change at Lexicon Pharmaceuticals is significant as it involves the departure of the President and COO, who also served as the principal financial officer. However, the transition plan, including the appointment of Kristen L. Alexander and Wade's continued consultancy, suggests a stable transition, leading to a neutral short-term impact on the stock price.